Establishment and characterization of patient-derived xenograft of scrotal Paget's disease.

OBJECTIVE

To develop a patient-derived xenograft model (PDX) of Scrotal Paget's disease (SPD), providing an experimental tool for the screening of therapeutic drugs and the development of new drugs for SPD treatment.

METHODS

SPD tumor tissues were implanted into the subcutaneous area of the right scapula in male NOD-Scid mice to establish a PDX model. PDX tissues were characterized using H&E staining, immunohistochemistry, and PCR. Cisplatin chemotherapy's antitumor effects were assessed through ex vivo histoculture drug sensitivity test (HDST) with patient tumor tissues and in vivo experiments with the PDX model.

RESULTS

The patient-derived SPD tissues were tumorigenic in male NOD-Scid mice and remained stable upon serial passage. H&E staining confirmed the preservation of morphological features from the patient's tumor tissues. Immunohistochemistry showed protein expression patterns consistent with clinical presentation. PCR ruled out spontaneous murine lymphoma. HDST experiments indicated cisplatin sensitivity in the patient's tumor tissues. In vivo experiments demonstrated significant tumor growth inhibition in SPD PDX mice with cisplatin, without affecting mouse body weight.

CONCLUSION

A SPD PDX model was successfully established, the PDX tumors maintained the characteristics of the patient's original tumors.